中文簡介

關(guān)于新興藥物的專家意見提供了最快速發(fā)展的藥物類別和治療領(lǐng)域的專家評估。由主要專家編寫的新興藥物簡介是權(quán)威的、全面的和最新的。新興藥物的專家意見是必不可少的閱讀醫(yī)藥和學術(shù)科學家，研究規(guī)劃，醫(yī)藥產(chǎn)品經(jīng)理，臨床意見領(lǐng)袖和醫(yī)療保健規(guī)劃。制定關(guān)于新興藥物的專家意見的目的是對最重要的新興藥物技術(shù)提供專家評價。這些評估是根據(jù)它們對當前特定疾病管理的潛在影響。關(guān)于新興藥物的專家意見還包括關(guān)于新興藥物發(fā)展戰(zhàn)略的論文，其目的是對最有希望的藥物研究領(lǐng)域的商業(yè)和技術(shù)可行性提供一種可獲得和獨立的評估。

　　英文簡介

Expert Opinion on Emerging Drugs provides an expert assessment of the most rapidly advancing drug classes and therapeutic areas. Emerging Drugs profiles, prepared by leading experts, are authoritative, comprehensive and up-to date. Expert Opinion on Emerging Drugs is essential reading for pharmaceutical and academic scientists, research planners, pharmaceutical product mangers, clinical opinion leaders and healthcare planners. Expert Opinion on Emerging Drugs was devised with the intention of providing an expert evaluation of the most important emerging drug technologies. These are assessed in terms of their potential impact on the current management of specific diseases. Expert Opinion on Emerging Drugs also includes papers on Emerging Drug Development Strategies, which aim to provide an accessible and independent assessment of the commercial and technical viability of the most promising areas of drug research.

　　近年期刊自引率趨勢圖

　　JCR分區(qū)

JCR分區(qū)等級	JCR所屬學科	分區(qū)	影響因子
Q2	PHARMACOLOGY & PHARMACY	Q2	3.912

　　近年期刊影響因子趨勢圖

　　CiteScore數(shù)值

CiteScore	SJR	SNIP	學科類別	分區(qū)	排名	百分位
5.60	0.972	0.795	大類：Medicine 小類：Pharmacology (medical)	Q2	66 / 255	74%
			大類：Medicine 小類：Pharmacology	Q2	110 / 303	63%

　　相關(guān)醫(yī)學SCI期刊推薦

• BimonthlyJANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE
• MonthlyJOURNAL OF REHABILITATION MEDICINE
• QuarterlyPHARMACOLOGICAL REVIEWS
• QuarterlyJournal of Community Health Nursing
• MonthlyJOURNAL OF CLINICAL MICROBIOLOGY
• QuarterlyCANCER AND METASTASIS REVIEWS
• QuarterlyCLINICS IN PLASTIC SURGERY
• MonthlyActas Urologicas Espanolas
• Pain Research & Management
• Oncology Research and Treatment